Actavis looks set to top its recent buying spree with its largest acquisition yet, with a potential $25bn buy of Forest Laboratories.
Actavis in $25bn Forest buy
Actavis looks set to top its recent buying spree with its largest acquisition yet, with a potential $25bn buy of Forest Laboratories.
More from Alimentary/Metabolic
• By
Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.
• By
Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).
• By
The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.
• By
The company announced positive topline results for the oral GLP-1 drug in type 2 diabetes that beat expectations.
More from Therapy Areas
• By
The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.
• By
J&J secures EU approval for its IL-23 inhibitor Tremfya for ulcerative colitis, its third indication in the region, amid strong competition in the sector. EU approval is also awaited for Crohn’s disease.
• By
The drug maker presented data from two cohorts of a pivotal Phase IIb study in NMIBC. Cost and ease of administration offer the potential to benefit the drug commercially.